Keros Therapeutics (KROS) Stock Chart & Stock Price History $10.86 +0.34 (+3.23%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Keros Therapeutics Stock Price Performance 5 Day Performance+4.22%1 Month Performance-36.23%3 Month Performance-82.27%6 Month Performance-77.55%Year-To-Date Performance-31.40%1 Year Performance-79.49% Receive KROS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Stock Chart for Monday, January, 20, 2025 KROS Chart by TradingView Keros Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization01/17/2025$10.52$10.86+3.23%$11.63$10.742.99 million shs$439.91 million01/16/2025$10.42$10.52+0.96%$10.71$10.103.20 million shs$426.17 million01/15/2025$12.48$10.42-16.51%$10.90$9.7713.60 million shs$422.08 million01/14/2025$12.82$12.48-2.65%$13.04$12.221.13 million shs$505.53 million01/13/2025$14.56$12.82-11.95%$14.10$12.352.31 million shs$519.30 million01/10/2025$14.89$14.56-2.22%$14.69$13.961.61 million shs$589.78 million01/09/2025$14.89$14.89$15.78$14.82720,712 shs$603.15 million01/08/2025$15.84$14.89-6.00%$15.78$14.82720,712 shs$603.15 million01/07/2025$15.64$15.84+1.28%$16.49$15.60868,677 shs$641.63 million01/06/2025$16.10$15.64-2.86%$16.47$15.59937,257 shs$633.53 million Get the Latest News and Ratings for KROS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 01/03/2025$15.92$16.10+1.13%$16.52$15.74752,461 shs$652.16 million01/02/2025$15.83$15.92+0.57%$16.70$15.82524,203 shs$644.87 million01/01/2025$15.83$15.83$15.93$15.33853,070 shs$641.23 million12/31/2024$15.64$15.83+1.21%$15.93$15.33853,070 shs$641.23 million12/30/2024$16.42$15.64-4.75%$16.51$15.511.32 million shs$633.53 million12/27/2024$16.81$16.42-2.32%$17.25$16.28862,054 shs$665.17 million12/26/2024$16.71$16.81+0.60%$16.89$16.30998,095 shs$680.97 million12/25/2024$16.71$16.71$17.12$16.63378,972 shs$676.87 million12/24/2024$17.12$16.71-2.39%$17.12$16.63378,972 shs$676.87 million12/23/2024$17.03$17.12+0.53%$17.50$16.88974,212 shs$693.48 million12/20/2024$16.92$17.03+0.65%$17.64$16.621.47 million shs$689.83 million12/19/2024$17.13$16.92-1.23%$17.08$16.311.70 million shs$685.38 million Related Companies Beam Therapeutics Stock Price Chart Centessa Pharmaceuticals Stock Price Chart Mesoblast Stock Price Chart IDEAYA Biosciences Stock Price Chart Agios Pharmaceuticals Stock Price Chart Apogee Therapeutics Stock Price Chart Tarsus Pharmaceuticals Stock Price Chart Iovance Biotherapeutics Stock Price Chart Amphastar Pharmaceuticals Stock Price Chart Disc Medicine Stock Price Chart Receive KROS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:KROS) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
